US103545A - Improved medical compound - Google Patents

Improved medical compound Download PDF

Info

Publication number
US103545A
US103545A US103545DA US103545A US 103545 A US103545 A US 103545A US 103545D A US103545D A US 103545DA US 103545 A US103545 A US 103545A
Authority
US
United States
Prior art keywords
improved medical
medical compound
compound
philip
becker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Publication date
Application granted granted Critical
Publication of US103545A publication Critical patent/US103545A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender

Definitions

  • This invention consists in a new compound of medicinal substances for the cure of fever and ague, and other kindred diseases, the said substances being as follows, mixed in the quantities, or thereabout, as stated: quinine, one dram; Peruvian bark, one ounce; rhubarb, one-half ounce; alcohol, one gill; water, one gill; winter-green, (liquid,) one tea-spoonful; molasses or sirup, (best,) one quart, to be mixed in a bottle and kept in a cool place, and to be administered about a half-hour before meals, three times a day, about a tablespoonful to a dose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

UNITED STATES PATENT OFFICE.
PHILIP BECKER, OF SOUTH BETHLEHEM, PENNSYLVANIA.
IMPROVED MEDICAL COMPOUND.
Specification forming part of Letters Patent No. 103, 545, dated May 31, 1870.
To all whom it may concern:
Be it known that I, PHILIP BECKER, of South Bethlehem, in the county of N orthampton and State of Pennsylvania, have invented a new and Improved Medical Compound; and I do hereby declare that the following is a full, clear, and exact description thereof, which will enable others skilled in the art to make and use the same.
This invention consists in a new compound of medicinal substances for the cure of fever and ague, and other kindred diseases, the said substances being as follows, mixed in the quantities, or thereabout, as stated: quinine, one dram; Peruvian bark, one ounce; rhubarb, one-half ounce; alcohol, one gill; water, one gill; winter-green, (liquid,) one tea-spoonful; molasses or sirup, (best,) one quart, to be mixed in a bottle and kept in a cool place, and to be administered about a half-hour before meals, three times a day, about a tablespoonful to a dose.
If the medicine thus described is taken when the disease first sets in, three doses will be sufficient to check it; but it will be necessary to continue the cure a few days.
Before taking the medicine, and while taking it, a powerful physio should be taken to carry off the disease, according to the character and nature of the malady and the constitution of the patient. The use of the medicine should be continued from two to four days.
Having thus described my invention, I claim as new and desire to secure by Letters Patent- The improved medical compound, consisting of the above-described ingredients, mixed in about the proportions specified.
PHILIP BECKER.
WVitnesses:
H. J. REEDER, A. PoYoK, J AGOB 'ZoRN.
US103545D Improved medical compound Expired - Lifetime US103545A (en)

Publications (1)

Publication Number Publication Date
US103545A true US103545A (en) 1870-05-31

Family

ID=2173030

Family Applications (1)

Application Number Title Priority Date Filing Date
US103545D Expired - Lifetime US103545A (en) Improved medical compound

Country Status (1)

Country Link
US (1) US103545A (en)

Similar Documents

Publication Publication Date Title
Kew et al. Arsenic and mercury intoxication due to Indian ethnic remedies
Cupp Herbal remedies: adverse effects and drug interactions
Berning et al. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.
Fallah et al. Efficacy of topiramate alone and topiramate plus vitamin D3 in the prophylaxis of pediatric migraine: a randomized clinical trial
Krudsood et al. Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP®) and artemether-lumefantrine (Coartem®/Riamet®) in the treatment of acute uncomplicated falciparum malaria in Thailand
Munster et al. Imipramine (Tofrānil) in the treatment of enuresis
US103545A (en) Improved medical compound
FR3021224A1 (en) PHYTOMEDICAMENT FOR HIV
MAY et al. Parkinsonian reactions following chlorpromazine and reserpine: similar reactions in the same patients
DENBER et al. Problems in evaluation of R-1625
Gupta et al. Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study
Brunel et al. A double‐blind, placebo controlled, randomized trial to assess the impact of a monthly administration of 50,000 IU of vitamin D3 for 6 months on serum levels of 25‐hydroxyvitamin D in healthy young adults
Cortés‐Moreno et al. Anorectic efficacy and safety of the diethylpropion‐topiramate combination in rats
US102686A (en) Improvement in compounds for treating- rheumatism
IL94601A (en) Pharmaceutical compositions comprising naftopidil for therapy of dysuria
OLTMAN et al. Further report on protein-bound iodine in patients receiving perphenazine
DARLING Isocarboxazid (Marplan) in ambulatory psychiatric patients
US113713A (en) Improvement in medical compounds or bitters
US117870A (en) Improvement in medical compounds for treating rheumatism
US90962A (en) Improved medical compound
Pehrson et al. Treatment with praziquantel in a patient with schistosomiasis and chronic renal failure
US79641A (en) Improved oathaetio igzenge
US111655A (en) Improvement in medical compounds
US107024A (en) Improvement in medical compound tor the cure op fever and ague
US71549A (en) Executrix